India Depression Therapeutics Market Report 2022 to 2030

India Depression Therapeutics Market Analysis

$ 3999

The India depression therapeutics market is expected to witness growth from $184 Mn in 2022 to $345 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030. The increasing investments in research and development projects for depression in India along with supportive government policies are responsible for the growth of the market. The Indian depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Mediwin Pharmaceuticals, Zydus Cadila, and GlaxoSmithKline are the major players in the Indian depression therapeutics market.

ID: IN10INPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Dr. Parul Choudhary

Buy Now

India Depression Therapeutics Market Executive Analysis

The India depression therapeutics market size is at around $184 Mn in 2022 and is projected to reach $345 Mn in 2030, exhibiting a CAGR of 8.2% during the forecast period. A staggering $1.07 Bn has been set aside for health expenditures in the Union Budget 2023, an increase of $0.02 Bn or 2.71 % from $1.04 Bn in FY23. The AYUSH, health and family welfare and finance ministries in India are responsible for allocating the entire Union health funding. For 2023–24, the total budget for health across all three departments is $1.3 Bn. This is slightly less than the planned amount from the previous year, which was approximately $1.32 Bn. But it's crucial to remember that despite this allocated amount in 2022–23 for the health sector, the revised estimate was cut to $111 Bn for the fiscal year 2022–23.

Approximately 2,00,000 Indians commit suicide each year. If suicide attempts are taken into account, the figures become even greater. A report states that there will be 56,675,969 instances of depression in India in 2022, with a prevalence rate of 4.50%.In most cases, depression brought on by reactive disorders can be treated with psychotherapy and patience without the use of drugs. In severe cases, those with a family history of major depression, or those who have had previous episodes are recommended drug therapy. The more recent antidepressants used as first-line treatments include selective serotonin reuptake inhibitors (SSRIs) and novel antidepressants. Although the newer medications have a broader margin of safety, tricyclic antidepressants (TCAs) have a limited therapeutic index. Due to the dietary and other limitations needed, monoamine oxidase (MAO) inhibitors are typically used as third-line medications for depression (after SSRIs, TCAs, or atypical antidepressants have failed).

All forms of depression can be treated with electroconvulsive therapy, which also quickly ends a manic phase. In particular, it works wonders for the delusions and agitation that are frequently present in senior depression as well as postpartum depression and severe depression. When a person's health prevents them from taking antidepressants, when they are not responsive to these drugs, or when they are extremely suicidal, it is suggested. Amitril-25, Duloser-20, and Exilite Forte are some of the best medicines for the treatment of depression in India.

India Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Lower productivity, higher rates of morbidity and mortality, and a rise in alcohol and substance use among a large portion of the population of India can all be attributed to depression. Therefore, therapy for depression is receiving more focus to address these issues. Growth is anticipated to be fuelled during the forecast period by India's propensity for having favourable reimbursement policies for medications and treatments resulting in the expansion of India's depression therapeutics market.

Market Restraints

Depression and other mental health conditions continue to carry an immense stigma in India, despite efforts to mitigate prejudice toward mental disease. Ayurveda and yoga are popular traditional and complementary therapies in India that could be used as an option to Western-style antidepressants. The market proportion of antidepressant drugs may decline as a result. Treatment for depression can often be very costly. Due to their high cost, patients without access to health insurance or reputable primary care centres cannot afford such treatments. This might limit the India depression therapeutics market expansion in the ensuing years.

Competitive Landscape

Key Players

Bionics Remedies (IND)
Ambit Bio Medix (IND)
Elixir Pharma (IND)
Mediwin Pharmaceuticals (IND)
Zydus Cadila (IND)
GlaxoSmithKline
Elly Lilly
Allergan
Takeda Pharmaceutical
Intellipharmaceutics
Otsuka Holdings
H.Lundbeck
Apotex,

Healthcare Policies and Regulatory Landscape

To increase access to mental healthcare facilities, the Indian government introduced the National Mental Health Program in 1982. The program's purposes include lowering the disgrace associated with mental disease and offering mental health support to people in both urban and rural regions. The Mental Healthcare Act, of 2017 mandates insurance firms to provide coverage for mental health diseases, including depression. This suggests that insurance plans support mental health treatment, including hospitalization. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants are among the medicines for treating depression that is registered on the Essential Medicines List maintained by the Indian government. (TCAs). Insurance plans provide coverage for these drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.